替吉奥联合顺铂或奥沙利铂治疗进展期胃癌的疗效观察  

S-I plus cisplatin versus S-I plus oxaliplatin for the treatment of advanced gastric cancer

作　　者：卢玮冬[1] 许震[1] 张敏[1] 王少开[1] 

机构地区：[1]江苏省张家港市第一人民医院苏州大学附属张家港医院肿瘤科,215600

出　　处：《中国老年保健医学》2016年第4期53-55,共3页Chinese Journal of Geriatric Care

摘　　要：目的观察替吉奥联合顺铂或奥沙利铂治疗进展期胃癌的临床疗效。方法 2011年1月-2014年9月共收集我院肿瘤科采用SP和SOX方案治疗的72例进展期胃癌患者为研究对象,对其资料进行回顾性分析。根据患者所接受的化疗方案,将患者分为SP组（36例）和SOX组（36例）。SP组和SOX组的治疗方案分别为替吉奥联合顺铂及替吉奥联合奥沙利铂。每例患者须完成两个及两个以上的疗程方可评估疗效。观察两组患者的临床疗效及不良反应。结果所有患者均可评估疗效,两组患者的总有效率相比无显著差异（P〉0.05）。两组患者的不良反应发生率相比,无显著差异（P〉0.05）。结论治疗进展期胃癌患者,采用SP和SOX化疗方案,近期疗效均较好,且对不良反应均可耐受。Objectives To observe the clinical curative effect of S-I plus cisplatin versus S-I plus oxaliplatin for the treatment of advanced gastric cancer. Methods In a retrospective study,clinical outcomes of 72 patients with advanced gastric cancer were analyzed. The subjects were divided into two groups according to the regimen received： SOX group（ 36 cases） and SP group（ 36 cases）. The patients in SOX group received S-1 plus oxaliplatin,while the SP group received S-I plus cisplatin. Each patient was required to complete two or more than two courses of treatment can be evaluated. The clinical efficacy and adverse reactions of the two groups were observed. Results All patients were evaluated for efficacy and safety. The response rate was not significant different between the two groups（ P〉0.05）. There was no significant difference in the incidence of adverse reactions between the two groups（ P〉0.05）. Conclusions Both SOX and SP are effective and well-tolerated for the treatment of advanced gastric cancer. No statistically significant difference is noted in response rate between two treatment groups.

关 键 词：替吉奥 顺铂 奥沙利铂 进展期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]